-
The Food and Drug Administration (FDA) and the Federal Trade Commission have issued a joint call to remove products from the market that make unproven claims to treat, cure, and prevent sexually transmitted diseases (STDs).
-
Results of a new study indicate patients who have tested positive for herpes simplex virus type 2 (HSV-2) but don't have symptoms or genital lesions still experience virus shedding during subclinical episodes.
-
In this issue: Calcium supplements and MI; birth control pills and VTE; ACE inhibitors and breast cancer risk; spending on pharmaceuticals; and FDA actions.
-
Although the annual incidence of all gynecological malignancies remains between 75,000 and 80,000, a far greater number of women with this history are survivors.
-
This publication is an update on osteoporosis screening from the 2002 U.S. Preventive Services Task Force (USPSTF) recommendation.
-
Over the years, different tocolytics have been in vogue, only to be discarded later because meta-analyses showed that the agent simply did not work. This month's review will focus on nifedipine, a medication that has been in and out of favor for more than 20 years.
-
-
In the vulvar vestibulitis clinical trial conducted at the University of Rochester between 2002 and 2007, patients with vulvar vestibulitis syndrome (localized provoked vulvodynia) were enrolled in a 12-week randomized, placebo-controlled treatment trial.
-
The investigators prospectively enrolled and followed a cohort of 97 teens before and six, 12, and 18 months after starting DMPA.
-
Is your facility participating in National HIV Testing Day on June 27? If not, you may be missing an important community outreach opportunity to help people learn their HIV status.